Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
halobetasol
- Development stage
- Approved
- Lead developer
- Valeant Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Topical
01
Overview
Halobetasol (also known as ulobetasol) is a **super high potency topical corticosteroid** used primarily to treat inflammatory skin conditions, particularly **plaque psoriasis** and **eczema**. It works by activating natural substances in the skin to **reduce swelling, redness, and itching**.
- Brand names
- UltravateBryhaliLexetteHalonate
- Other names
- ulobetasol
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on halobetasol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on halobetasol.